A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.
Also called NCT07285655
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 344 participants
- Sponsor
- Liquidia Technologies, Inc.
- Registry
-
NCT07285655
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Austria, Belgium, Canada, France, Germany, Italy, Latvia, Portugal, Spain, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07285655. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2029-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- Acronym
- Re-Spire
- Condition
- Pulmonary Hypertension Due to Lung Disease (Disorder)
- Intervention (Drug)
- L606
- Intervention (Drug)
- Placebo
- Lead sponsor
- Liquidia Technologies, Inc.
Record details
- Record id
cardio:ct-nct07285655- Content hash
114ab576d39aecdf79e5d050cf38c543c430da4e923ba12660977e0ca4e3133d